Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,501.24
(
0.77%
)
US TECH 100
28,788.80
(
0.70%
)
Dow Jones
50,063.46
(
0.75%
)
Brent Oil
104.50
(
0.30%
)
Bitcoin
80,877.84
(
-0.22%
)
News Focus
News Focus
Post# of 257566
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122982
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: genisi post# 67271

Thursday, 10/13/2011 9:53:37 AM

Thursday, October 13, 2011 9:53:37 AM

Post# of 257566
BAX starts phase-3 trial of recombinant factor for von Willebrand disease:

http://finance.yahoo.com/news/Baxter-Initiates-Phase-III-bw-32737753.html?x=0&.v=1

Plasma-based products are already approved for VWD (e.g. #msg-44288894), but BAX 111 is the only recombinant factor from any company in clinical development for VWD.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Discover What Traders Are Watching

Explore small cap ideas before they hit the headlines.

Join Today